Eating Our Seed Corn
Executive SummaryThe drug industry's preoccupation with late-stage products means they're largely ignoring early-stage companies. But unlike earlier years, these biotechs have no financing alternative: the stock market now marches in lockstep with Big Pharma trends. But as the extraordinary valuations of the large biotechs shows, the early-stage companies of today can be the late-stage companies of tomorrow--and the source of Big Pharma's late-stage product opportunities. If drug firms don't act now to encourage early-stage investment--either through lobbying for governmental investment incentives or through their own venture investing--they may, in focusing so exclusively on late-stage deals, be eating their own seed corn.
You may also be interested in...
December's ANDA rush has provided the largest monthly haul in two years. However, the month may be losing its influence over the US FDA's annual submission total.
Among the Korean firms presenting at J.P. Morgan, Hanmi laid out its strategy for obesity and other core pipeline assets, Celltrion focused on its expanding biosimilar pipeline and China plans and LG Chem unveiled new R&D progress.